MedPath

MaaT Pharma Share Price Rises on Positive Clinical Trial Results

MaaT Pharma's share price surged over 19% following the announcement of successful Phase 3 clinical trial results for its MaaT013 treatment in acute graft-versus-host disease, marking a significant advancement in gastrointestinal response rates.

MaaT Pharma experienced a significant surge in its share price, climbing over 19% on the Paris Bourse, following the announcement of the success of its Phase 3 clinical trial for MaaT013 in treating acute graft-versus-host disease (aGvH). The study met its primary endpoint with a 62% overall gastrointestinal response rate at day 28, surpassing the expected 38% response rate. This 'unprecedented' level of efficacy has led analysts to increase the product's probability of success from 80% to 95% and raise the price target from 21 to 22 euros. MaaT013 aims to restore the symbiotic relationship between the patient's gut microbiota and immune system, improving long-term survival rates in 3rd-line GI-aGvH. The biotech company plans to file a marketing authorization application in Europe by mid-2025, ahead of schedule.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

MaaT Pharma SA Advances in Gut Microbiome-Driven Therapies for Cancer Treatment

MaaT Pharma SA, a late-stage clinical company, is making significant progress in the development of gut microbiome-driven therapies aimed at modulating the immune system and improving cancer survival. The company's pipeline includes MaaT013, MaaT033, and MaaT03X, targeting acute graft versus host diseases, acute myeloid leukemia, and solid tumors, respectively.

MaaT013 Shows Promise in Phase 3 Trial for GI-aGvHD

MaaT Pharma's MaaT013 met its primary endpoint in the Phase 3 ARES trial, demonstrating a 62% gastrointestinal overall response rate (GI-ORR) in patients with GI-aGvHD.

Cutia Therapeutics' Novel Drug Shows Promise in Phase II Submental Fat Treatment Trial

Cutia Therapeutics has successfully completed Phase II clinical trials for CU-20401, demonstrating significant efficacy in treating submental fat accumulation. The drug showed a favorable safety profile, marking a potential advancement in aesthetic medicine.

Sagimet Biosciences' Denifanstat Shows Promise in MASH Treatment, Stock Surges

Sagimet Biosciences' Denifanstat receives FDA Breakthrough Therapy designation for metabolic dysfunction-associated steatohepatitis (MASH), accelerating its development and review process.

Candel Therapeutics' CAN-2409 Achieves Primary Endpoint in Phase III Prostate Cancer Trial

Candel Therapeutics' CAN-2409, combined with radiation therapy, significantly improved disease-free survival in localized prostate cancer patients in a Phase III trial.

Cardiol Therapeutics Advances CardiolRx into Phase III Trial for Recurrent Pericarditis Following Positive Phase II Results

Cardiol Therapeutics is advancing its drug, CardiolRx, into a Phase III clinical trial (MAVERIC-3) for recurrent pericarditis after promising Phase II results.

Biofrontera's Ameluz Demonstrates High Efficacy in Phase III sBCC Trial

Biofrontera's Ameluz-PDT therapy met the primary endpoint, showing 65.5% success in complete clearance of superficial basal cell carcinoma (sBCC) lesions, compared to 4.8% with placebo.

Shuttle Pharmaceuticals' Ropidoxuridine Shows Promise in Phase 2 Glioblastoma Trial

Shuttle Pharmaceuticals has successfully dosed the first three patients in a Phase 2 trial of ropidoxuridine for glioblastoma.

Viridian Therapeutics' Veligrotug Achieves Positive Phase III Results in Thyroid Eye Disease

Viridian Therapeutics' veligrotug met all primary and secondary endpoints in the Phase III THRIVE trial for active thyroid eye disease (TED).

MaaT Pharma Announces Global Offering to Fund Microbiome Ecosystem Therapies Development

MaaT Pharma, a clinical-stage biotech company, has launched a global offering of approximately 18 million euros to fund the development of its Microbiome Ecosystem Therapies. The offering includes a reserved offering to specific investors and a public offering to retail investors, with the aim of supporting the company's Phase 3 trial for MaaT013 and expanding its pipeline development.

Reference News

[1]
MaaT Pharma: share price rises on positive clinical trial - MarketScreener
marketscreener.com · Jan 9, 2025

MaaT Pharma's stock surged over 19% on the Paris Bourse after its Phase 3 trial for MaaT013 in aGvH showed a 62% gastroi...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy